Total Payments
$2,433
2024 Payments
$483.43
Companies
24
Transactions
118
Medicare Patients
24,060
Medicare Billing
$2.8M
Payment Breakdown by Category
Food & Beverage$2,386 (98.1%)
Education$46.91 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,386 | 117 | 98.1% |
| Education | $46.91 | 1 | 1.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $489.23 | 33 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $351.85 | 15 | $0 (2023) |
| Lundbeck LLC | $194.57 | 10 | $0 (2024) |
| Indivior Inc. | $178.10 | 8 | $0 (2024) |
| ABBVIE INC. | $172.91 | 7 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $167.41 | 6 | $0 (2019) |
| ITI, Inc. | $127.38 | 4 | $0 (2023) |
| ACADIA Pharmaceuticals Inc | $127.12 | 6 | $0 (2020) |
| Alkermes, Inc. | $118.77 | 5 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $81.82 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $483.43 | 21 | Otsuka America Pharmaceutical, Inc. ($99.31) |
| 2023 | $578.08 | 26 | Otsuka America Pharmaceutical, Inc. ($101.69) |
| 2022 | $307.32 | 16 | Indivior Inc. ($122.90) |
| 2021 | $126.04 | 4 | ITI, Inc. ($71.72) |
| 2020 | $120.14 | 6 | ACADIA Pharmaceuticals Inc ($55.65) |
| 2019 | $373.94 | 15 | Avanir Pharmaceuticals, Inc. ($133.16) |
| 2018 | $137.29 | 7 | ACADIA Pharmaceuticals Inc ($71.47) |
| 2017 | $306.40 | 23 | Otsuka America Pharmaceutical, Inc. ($133.12) |
All Payment Transactions
118 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.22 | General |
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $22.93 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/07/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: PSYCHIATRY | ||||||
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $31.67 | General |
| Category: Psychiatry/Psychology | ||||||
| 10/24/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $22.07 | General |
| Category: PSYCHIATRY | ||||||
| 10/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: NEUROSCIENCE | ||||||
| 10/14/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $18.84 | General |
| Category: PSYCHIATRY | ||||||
| 08/23/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $14.35 | General |
| Category: PSYCHIATRY | ||||||
| 08/22/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: PSYCHIATRY | ||||||
| 06/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.53 | General |
| Category: NEUROSCIENCE | ||||||
| 05/13/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), REXULTI | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: PSYCHIATRY | ||||||
| 05/06/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $23.26 | General |
| Category: Neurology | ||||||
| 05/03/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $32.06 | General |
| Category: NEUROSCIENCE | ||||||
| 05/02/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: Psychology/Psychiatric | ||||||
| 04/25/2024 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $25.83 | General |
| Category: BH | ||||||
| 04/22/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $19.52 | General |
| Category: PSYCHIATRY | ||||||
| 04/04/2024 | Otsuka America Pharmaceutical, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: NEUROLOGY | ||||||
| 03/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $25.09 | General |
| Category: PSYCHIATRY | ||||||
| 02/12/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $23.87 | General |
| Category: Psychology/Psychiatric | ||||||
| 02/08/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: PSYCHIATRY | ||||||
| 01/23/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $27.73 | General |
| Category: PSYCHIATRY | ||||||
| 12/14/2023 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $29.37 | General |
| Category: BH | ||||||
| 12/08/2023 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $30.43 | General |
| Category: PSYCHIATRY | ||||||
| 11/28/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.30 | General |
| Category: NEUROSCIENCE | ||||||
| 11/27/2023 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $21.57 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 21,222 | 167,077 | $2.4M | $2.1M |
| 2022 | 12 | 1,154 | 3,853 | $511,481 | $228,190 |
| 2021 | 8 | 684 | 3,023 | $455,609 | $205,773 |
| 2020 | 7 | 1,000 | 3,359 | $549,262 | $224,130 |
Total Patients
24,060
Total Services
177,312
Medicare Billing
$2.8M
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | Office | 2023 | 20,537 | 164,437 | $2.0M | $1.9M | 98.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 181 | 1,089 | $167,918 | $70,422 | 41.9% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 71 | 684 | $82,080 | $41,174 | 50.2% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2023 | 91 | 100 | $28,288 | $13,501 | 47.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 59 | 208 | $28,649 | $13,282 | 46.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 100 | 115 | $33,420 | $10,681 | 32.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 56 | 62 | $26,071 | $8,801 | 33.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 31 | 89 | $14,685 | $8,795 | 59.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 27 | 92 | $22,617 | $8,563 | 37.9% |
| 90837 | Psychotherapy, 1 hour | Office | 2023 | 11 | 71 | $17,708 | $8,173 | 46.2% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 14 | 54 | $10,800 | $3,289 | 30.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 19 | 19 | $4,724 | $2,887 | 61.1% |
| 90834 | Psychotherapy, 45 minutes | Facility | 2023 | 14 | 32 | $5,330 | $2,159 | 40.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 25 | $5,550 | $1,110 | 20.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 173 | 901 | $136,218 | $52,968 | 38.9% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Office | 2022 | 88 | 619 | $74,280 | $34,117 | 45.9% |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | Office | 2022 | 171 | 526 | $78,900 | $32,044 | 40.6% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2022 | 171 | 527 | $31,620 | $22,522 | 71.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 60 | 310 | $36,428 | $21,902 | 60.1% |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | Office | 2022 | 171 | 525 | $36,750 | $12,848 | 35.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 64 | 76 | $30,400 | $12,357 | 40.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 46 | 117 | $18,452 | $11,584 | 62.8% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2022 | 74 | 80 | $22,590 | $11,484 | 50.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 73 | 89 | $26,156 | $7,662 | 29.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 23 | 42 | $9,450 | $3,617 | 38.3% |
About Dr. Aqeel Khan, M.D
Dr. Aqeel Khan, M.D is a Psychiatry healthcare provider based in Bloomingdale, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629046735.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aqeel Khan, M.D has received a total of $2,433 in payments from pharmaceutical and medical device companies, with $483.43 received in 2024. These payments were reported across 118 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($2,386).
As a Medicare-enrolled provider, Khan has provided services to 24,060 Medicare beneficiaries, totaling 177,312 services with total Medicare billing of $2.8M. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Psychiatry
- Location Bloomingdale, IL
- Active Since 03/14/2006
- Last Updated 06/15/2021
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1629046735
Products in Payments
- REXULTI (Drug) $409.05
- ABILIFY MAINTENA (Drug) $256.48
- SPRAVATO (Drug) $207.78
- NUEDEXTA (Drug) $185.68
- CAPLYTA (Drug) $180.20
- PERSERIS (Drug) $178.10
- VRAYLAR (Drug) $172.91
- NUPLAZID (Drug) $127.12
- INVEGA SUSTENNA (Drug) $126.21
- ARISTADA (Drug) $76.13
- COBENFY (Drug) $54.60
- Aristada 441 mg (Drug) $42.64
- INGREZZA (Drug) $41.07
- Auvelity (Drug) $39.66
- Zubsolv (Drug) $38.98
- QELBREE (Drug) $33.38
- AMYVID (Drug) $28.06
- UZEDY (Drug) $23.26
- Lucemyra (Drug) $23.02
- SUBVENITE (Drug) $19.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.